Removing logistical barriers to improve clinical trial retentionWe all know how long and arduous the clinical trial road is for sites and sponsors – but Share XRemoving logistical barriers to improve clinical trial retentionhttps://pharmaphorum.com/views-analysis-patients/removing-logistical-barriers-to-improve-clinical-trial-retention/
Towards patient centricity: PfizerIn a new series Amanda Barrell looks at how different companies are turning patient centricity into a reality. Share XTowards patient centricity: Pfizerhttps://pharmaphorum.com/views-and-analysis/towards-patient-centricity-pfizer/
Why pharma isn’t collaborating with patient organisations as much as it shouldPatient centricity has rapidly gone from a fringe idea to a fundamental principle across the industry, but are Share XWhy pharma isn’t collaborating with patient organisations as much as it shouldhttps://pharmaphorum.com/views-and-analysis/why-pharma-isnt-collaborating-with-patient-organisations-as-much-as-it-should/
The rise and rise of patient centricityGeorge Underwood looks at the rapid growth of patient centricity over the last few years and considers what Share XThe rise and rise of patient centricityhttps://pharmaphorum.com/views-and-analysis/the-rise-and-rise-of-patient-centricity/
Listening to the patient voice: Why developing new dementia treatments is everyone’s jobDeveloping life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and Share XListening to the patient voice: Why developing new dementia treatments is everyone’s jobhttps://pharmaphorum.com/views-and-analysis/listening-to-the-patient-voice-why-developing-new-dementia-treatments-is-everyones-job/
Building our own community for an ultra-rare diseaseBo Bigelow shares the story of his daughter Tess, who has an ultra-rare genetic disorder with only 51 Share XBuilding our own community for an ultra-rare diseasehttps://pharmaphorum.com/views-and-analysis/building-our-own-community-for-an-ultra-rare-disease/
Time to build evidence for patient involvement in researchPatient and public involvement (PPI) may be increasingly seen as the “right thing to do”, but without systematic Share XTime to build evidence for patient involvement in researchhttps://pharmaphorum.com/views-analysis-patients/time-to-build-evidence-for-patient-involvement-in-research/
Lung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, Share XLung cancer’s patient information gap: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/lung-cancers-patient-information-gap
Understanding muscular dystrophyChris Anselmo, who has a rare form of muscular dystrophy, hopes to educate pharma on the patient journey Share XUnderstanding muscular dystrophyhttps://pharmaphorum.com/views-analysis-patients/understanding-muscular-dystrophy/
